Get started

Drug

DRUG (Bright Minds Biosciences Inc.): Massive 2,000% Surge!DRUG (Bright Minds Biosciences Inc.) Super Move Captured with Risological Swing Trader We entered a long position on 14th October at 1.23 using the daily time frame, catching this explosive upward movement with the precision of the Risological Swing Trader. The indicator identified the perfect entry point, allowing us to ride this massive surge effortlessly. As of now, the price has reached $26.90, delivering an exceptional return. Target Points Achieved: TP 1: 1.40 TP 2: 1.68 TP 3: 1.95 TP 4: 2.12 This trade exemplifies the strength of the Risological Swing Trader in identifying major opportunities and turning them into extraordinary gains.
NASDAQ:DRUGLong
by ProfitsNinja
11
JNJ | I Love It Here | LONGJohnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
NYSE:JNJLong
by DivergenceSeeker
2
The RAD Lottery Ticket Play For A Desperate PortfolioWith the rapidly expanding prescription drug market, one may take a flyer out on this stock (Rite Aid). As most of you know Rite Aid sold a vast amount of their stores to Walgreens, but the real story is those stores that were sold were in key geographic locations and created large amounts of revenue. I have been tracking this stock since 2013, and the common theme is this company is on the way back to the top. As price action shows over time this company is on the fast track to nowhere. The company is in crippling debt, and the revenue raised by the sale of store locations still isn't enough.
R
by hesswg48
Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million. Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017 Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows: Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS) Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments: Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor Anticipated Milestones CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
CLong
by StockGuild
Biotech's 40% Bear Market is OverThere is one useful way to determine when a trend is over and that is using a 50% "speedline" of a move. The decline from $400 in $IBB, the IShares Nasdaq Biotechnology Index Fund back in July 2015 and then tumbled 40% to $240 on February 9th, 2016 and later retested $240 on June 27, 2016. The mid-point of that decline is $320 and a line drawn from the top at $400 down through the $320 level on June 27th gives you a line that is now down below $275 and that line has been violated to the upside, retested and is turning back up again and THIS TIME it is with President Trump pushing for faster "time to market" in exchange for lower drug prices. Will the deal go through and will it make a difference? Time will tell. For now, the Yellen-Bubble-popping bear market has been dramatic since August 2015 as it tumbled a whopping 40%. But there might be signs of life here in Biotech Bubble land, even with fears of price gouging still lingering over these stocks . For now: Average in over the next 2-3 months and see if this story pans out. Tim 12:31AM EST February 2, 2017 280.42 last $IBB. Other symbols for Biotech $FBT, $XBI, $BBH
NASDAQ:IBBLong
by timwest
11